Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATHE NASDAQ:IMCC NASDAQ:KLTO NASDAQ:NBRV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATHEAlterity Therapeutics$5.00-0.6%$4.78$1.00▼$7.00$44.62M0.67215,045 shs2,077 shsIMCCIM Cannabis$2.25+0.6%$2.80$1.29▼$7.12$11.81M2.2113,513 shs11,299 shsKLTOKlotho Neurosciences$0.74+0.5%$1.09$0.11▼$3.91$45.43M10.917.00 million shs527,304 shsNBRVNabriva Therapeutics$0.00$1.22▼$8.45$45.46M1.5329,344 shs15 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATHEAlterity Therapeutics-0.88%+2.12%-22.82%+16.21%+271.69%IMCCIM Cannabis-2.61%-11.46%-20.28%-17.34%-23.55%KLTOKlotho Neurosciences-2.32%-6.09%-40.11%+250.76%+73,659,900.00%NBRVNabriva Therapeutics0.00%0.00%0.00%0.00%+4,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationATHEAlterity Therapeutics2.6232 of 5 stars3.35.00.00.02.21.70.0IMCCIM Cannabis1.2024 of 5 stars0.05.00.00.04.40.00.0KLTOKlotho NeurosciencesN/AN/AN/AN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATHEAlterity Therapeutics 2.50Moderate Buy$12.00139.95% UpsideIMCCIM Cannabis 0.00N/AN/AN/AKLTOKlotho Neurosciences 0.00N/AN/AN/ANBRVNabriva Therapeutics 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATHEAlterity TherapeuticsN/AN/AN/AN/A$1.04 per shareN/AIMCCIM Cannabis$39.44M0.30N/AN/A$0.56 per share4.03KLTOKlotho NeurosciencesN/AN/AN/AN/A$0.17 per shareN/ANBRVNabriva Therapeutics$35.59M0.00N/AN/A$0.10 per share0.00Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATHEAlterity Therapeutics-$12.54MN/A0.00∞N/AN/AN/AN/AN/AIMCCIM Cannabis-$7.72M-$0.54N/AN/AN/A-4.19%-59.80%-5.15%11/12/2025 (Estimated)KLTOKlotho Neurosciences-$6.15M-$0.45N/A∞N/AN/A-325.88%-242.15%N/ANBRVNabriva Therapeutics-$57.19M-$19.20N/AN/AN/A-148.11%-365.53%-135.81%N/ALatest IMCC, NBRV, KLTO, and ATHE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2025Q2 2025KLTOKlotho NeurosciencesN/A-$0.12N/A-$0.12N/AN/A8/12/2025Q2 2025IMCCIM Cannabis-$0.1367-$0.0653+$0.0714-$0.07$12.88 million$9.21 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATHEAlterity TherapeuticsN/AN/AN/AN/AN/AIMCCIM CannabisN/AN/AN/AN/AN/AKLTOKlotho NeurosciencesN/AN/AN/AN/AN/ANBRVNabriva TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATHEAlterity TherapeuticsN/A3.84N/AIMCCIM Cannabis0.320.720.62KLTOKlotho NeurosciencesN/A135.73135.73NBRVNabriva Therapeutics0.120.850.52Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATHEAlterity Therapeutics2.14%IMCCIM Cannabis7.68%KLTOKlotho Neurosciences20.07%NBRVNabriva Therapeutics0.27%Insider OwnershipCompanyInsider OwnershipATHEAlterity Therapeutics38.80%IMCCIM CannabisN/AKLTOKlotho Neurosciences26.70%NBRVNabriva Therapeutics1.63%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATHEAlterity Therapeutics108.87 million5.43 millionNot OptionableIMCCIM Cannabis3405.25 millionN/ANot OptionableKLTOKlotho NeurosciencesN/A61.37 million44.99 millionN/ANBRVNabriva Therapeutics7032.02 million31.49 millionNot OptionableIMCC, NBRV, KLTO, and ATHE HeadlinesRecent News About These CompaniesNabriva Therapeutics plc (NBRVF)October 19, 2024 | finance.yahoo.comMeitheal gains rights to ContempoJuly 20, 2024 | thepharmaletter.comTMeitheal gains rights to CONTEPO from Nabriva in North AmericaJuly 19, 2024 | pharmaceutical-technology.comPNabriva Therapeutics PLC NBRVFApril 13, 2024 | morningstar.comMNabriva Therapeutics files patent for a dosing regimen for fosfomycin treatmentDecember 22, 2023 | pharmaceutical-technology.comPArbutus Biopharma Corporation: Arbutus Appoints Two New ExecutivesJuly 11, 2023 | finanznachrichten.deNBRV - Nabriva Therapeutics plcMay 26, 2023 | finance.yahoo.comBacterial Pneumonia Therapeutics Market Updated Report by Competitor Strategics till 2029February 28, 2023 | marketwatch.comNBRV Nabriva Therapeutics plcFebruary 25, 2023 | seekingalpha.comNabriva Therapeutics Provides Corporate UpdateJanuary 6, 2023 | finance.yahoo.comNabriva Therapeutics Shares Rise 11% After Positive Xenleta Trial DataNovember 28, 2022 | marketwatch.comNabriva Adds 9% On Positive Results From Study Of Xenleta In Cystic FibrosisNovember 28, 2022 | markets.businessinsider.comNabriva Announces Positive Results From Phase 1 Trial Of Lefamulin In Cystic Fibrosis; Stock UpNovember 28, 2022 | markets.businessinsider.comNabriva stock up after firm's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | bizjournals.comNabriva gains after announcing Phase 1 data for cystic fibrosis candidateNovember 28, 2022 | seekingalpha.comNabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic FibrosisNovember 28, 2022 | finance.yahoo.comNabriva's stock is up after sharing antibiotic newsNovember 28, 2022 | finance.yahoo.comNabriva's antibiotic shows promise as a potential cystic fibrosis treatmentNovember 28, 2022 | finance.yahoo.comNabriva Therapeutics describes new 12-epi-mutilin compounds to treat bacterial infectionsNovember 10, 2022 | bioworld.comBMontgomery County biopharmaceutical firm reducing workforce by 40%November 10, 2022 | finance.yahoo.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeIMCC, NBRV, KLTO, and ATHE Company DescriptionsAlterity Therapeutics NASDAQ:ATHE$5.00 -0.03 (-0.58%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.IM Cannabis NASDAQ:IMCC$2.25 +0.01 (+0.63%) As of 01:50 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.IM Cannabis Corp. engages in breeding, growing, and supply of medical cannabis products in Israel and Germany. It offers cannabis flowers and strain-specific cannabis extracts under the IMC brand; and dried flower, pre-rolls, minis, and full spectrum extracts offerings under the WAGNERS and BLKMKT brands. The company serves medical patients. IM Cannabis Corp. is headquartered in Tel Aviv, Israel.Klotho Neurosciences NASDAQ:KLTO$0.74 +0.00 (+0.49%) As of 01:26 PM EasternKlotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan's Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.Nabriva Therapeutics NASDAQ:NBRVNabriva Therapeutics plc, a biopharmaceutical company, engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company's product includes SIVEXTRO, an oxazolidinone-class antibacterial for the treatment of acute bacterial skin and skin structure infection (ABSSSI); and XENLETA, a semi-synthetic pleuromutilin antibiotic for oral and IV administration. It also develops XENLETA that is in Phase I clinical trial for the treatment of pediatric infections, as well as sexually transmitted infections, cystic fibrosis, ABSSSI, ventilator-associated bacterial pneumonia, complicated intra-abdominal infections, hospital-acquired bacterial pneumonia, acute bacterial skin and skin structure infections, osteomyelitis, and prosthetic joint infections. In addition, the company develops CONTEPO, an epoxide antibiotic for use in treating complicated urinary tract infections, as well as is in Phase I clinical trial for peri-operative prophylaxis. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MongoDB Roars Back to Life: It’s Not Too Late to Buy More Vertical Aerospace: An Analyst's Roadmap to a Potential Re-Rating AEHR Spikes 36% on Hyperscaler Order—Investors Should Take Notice From Debt to Liftoff: EchoStar's $23 Billion Catalyst Buffett’s Wisdom Could Spell Trouble for Palantir Shorts Tesla Just Had Its Best Day in 2 Months—Here’s What It Means Reynolds Consumer Products Stock Price: Insiders Signal a Bottom MP Materials: How One Move Redefined the U.S. Magnet Supply Chain Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access